Abstracts tagged "Tofacitinib and vaccines"

Abstract Number: 2393 • 2017 ACR/ARHP Annual Meeting
Evaluation of Live Zoster Vaccine in a Subset of Patients with Rheumatoid Arthritis Treated with Tofacitinib with or without Methotrexate, and Adalimumab with Methotrexate: Results from a Phase 3b/4 Randomized Trial
Leonard H. Calabrese¹, Carlos Abud-Mendoza², Stephen Lindsey³, Sang Heon Lee⁴, Liza Takiya⁵, Noriko Iikuni⁶, Koshika Soma⁷, Zhen Luo⁸ and Roy Fleischmann⁹, ¹Cleveland Clinic Foundation, Cleveland, OH, ²Hospital Central, San Luis Potosí, Mexico, ³Ochsner Medical Center, Baton Rouge, LA, ⁴Konkuk University School of Medicine, Seoul, Korea, Republic of (South), ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Shanghai, China, ⁹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Patients (pts) with RA are at increased risk for herpes…
Abstract Number: 2609 • 2016 ACR/ARHP Annual Meeting
The Effectiveness of Zoster Vaccine in RA Patients Subsequently Treated up to 19 Months with Tofacitinib
Kevin L Winthrop¹, Ann Wouters², Ernest H. Choy^3,4, Chudy Nduaka², Staci Abramsky², Pinaki Biswas², Lisy Wang⁵, Jennifer Hodge², Irina Lazariciu⁶, Koshika Soma², Christopher F Mojcik² and William F.C Rigby⁷, ¹Oregon Health and Sciences University, Portland, OR, ²Pfizer Inc, New York, NY, ³CREATE Center, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Great Britain, ⁴CREATE Center, Division of Infection and Immunity,, Cardiff University, Cardiff, United Kingdom, ⁵Pfizer Inc, Groton, CT, ⁶Quintiles, Saint-Laurent, QC, Canada, ⁷Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk for herpes zoster (HZ), and vaccination is recommended in patients over the age of 50 years,…
Abstract Number: 12L • 2015 ACR/ARHP Annual Meeting
Assessment of Immunogenicity of Live Zoster Vaccination (Zostavax®) in Rheumatoid Arthritis Patients on Background Methotrexate before and after Initiating Tofacitinib or Placebo
Kevin Winthrop IV¹, Ann Wouters², Ernest H. Choy³, Koshika Soma², Jennifer Hodge², Chudy Nduaka², Pinaki Biswas², Lisa K. McNeil², Sherry Passador², Christopher F. Mojcik² and William F.C. Rigby⁴, ¹Oregon Health and Sciences University, Portland, OR, ²Pfizer Inc, New York, NY, ³CREATE Center, Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁴Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Clinical guidelines recommend using live zoster vaccine (LZV) to prevent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].